Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis

Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of Chondroitin + Glucosamine Sulfate Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00860873

Enrollment

280

Registered

2009-03-12

Start date

2009-10-31

Completion date

2010-11-30

Last updated

2013-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthrosis

Brief summary

This study objective is to check the non-inferiority of the 2 formulations produced by EMS when compared with the same substances and pharmaceuticals forms of the product Condroflex (Zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and functional capacity that will be periodically measured by using the Visual Analog Scale of pain (VAS) and the questionnaire of Lequesne.

Interventions

DIETARY_SUPPLEMENTEMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)

Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg

DIETARY_SUPPLEMENTEMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)

Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg

DIETARY_SUPPLEMENTZodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)

Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg

DIETARY_SUPPLEMENTZodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)

Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients who agree with all aspects of the study and sign the Informed Consent; * Patients of both sexes; * Age above 30 years; * Clinical and radiological diagnosis of osteoarthritis; * Osteoarthritis in grades 1-2; * Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study.

Exclusion criteria

* Patients with a history of trauma clinically significant; * Patients who underwent surgery on joints affected; * Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others); * Pregnant patients and / or breastfeeding; * Patients with phenylketonuria; * Patients with clinical diagnosis of severe renal failure; * Patients with clinical diagnosis of severe liver disease; * Patients with clinical diagnosis of clotting disorders; * Patients who are being treated with anti-aggregating and / or anticoagulants; * Patients with sensitive components of the formula; * Patients with emotional disorders that interfere with the capture of data; * Patients who do not agree with the purposes of the study and did not sign the Informed Consent.

Design outcomes

Primary

Measure	Time frame
Decrease in pain.	V0 (Screening); V1 (Inclusion); V2 (2 weeks); V3 (4 weeks); V4 (8 weeks); V5 (12 weeks); V6 (24 weeks).

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026